Telangana Health Minister C. Damodar Raja Narasimha on Sunday (January 11) called for collective action to make Telangana the country’s first thalassemia-free State, outlining a long-term vision to ...
A major global medical breakthrough for thalassemia patients as the US drug regulator FDA approves Mitapivat, the first oral medicine for the genetic blood disorder. This new drug offers hope for a ...
The FDA approved mitapivat (Aqvesme) as a disease-modifying treatment for anemia in adults with alpha- or beta-thalassemia, a rare inherited blood disease that affects hemoglobin production. An oral ...
The FDA delivered a pair of holiday season approvals a week apart, signing off on Agios’ oral medicine Aqvesme for the treatment of anemia in adults with alpha- or beta-thalassemia on Dec. 23, and ...
LAHORE: World-renowned cricket umpire Aleem Dar, accompanied by celebrated actor and social worker Iftikhar Thakur, visited the Lahore Chamber of Commerce and Industry (LCCI) and met with LCCI ...
Aqvesme is expected to be available in late January 2026. The Food and Drug Administration (FDA) has approved Aqvesme™ (mitapivat) for the treatment of anemia in adults with alpha- or beta-thalassemia ...
The U.S. Food and Drug Administration (FDA) on Tuesday approved Agios Pharmaceuticals, Inc.’s (NASDAQ: AGIO) Aqvesme (mitapivat), an oral pyruvate kinase (PK) activator, for anemia in adults with ...
CAMBRIDGE, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients ...
What Is Aqvesme, and Why Does It Matter? Aqvesme (mitapivat) is a new oral medicine approved by the FDA for treating anemia in adults with alpha- or beta-thalassemia, including those who need and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results